Servier’s decision to exit a Parkinson’s disease pact has triggered belt tightening at French biotech Oncodesign Precision Medicine. The loss of a shot at a milestone prompted OPM to lay off ...

French pharma group Servier has formed a second partnership with Aitia focusing on the use of artificial intelligence and digital twins to help discover and develop new therapies for cancer.

Pieris Pharmaceuticals’ long-standing immuno-oncology alliance with Servier is being dissolved after a clinical trial of the lead drug in the alliance revealed a safety concern. In a Securities ...